Thinking about trading options or stock in Nike, Meta Platforms, Tesla, Walt Disney, or Netflix. a pill, which increases efficacy and limits side effects, purportedly. Screen for heightened risk individual and entities globally to help uncover hidden risks in business relationships and human networks. This press release features multimedia. You must click the activation link in order to complete your subscription. SAN DIEGO, Oct. 04, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Progenity) (Nasdaq: PROG), an innovative biotechnology company, today announced that it has entered into a definitive agreement with several institutional investors for the purchase and sale, in a registered direct offering priced at-the-market under Nasdaq rules, of 13,333,334 shares of the Company's common stock, at a purchase price of $1.50 per share. Once swallowed, the OBDS capsule is designed to transit the intestinal tract and trigger in the small intestine, where it will use liquid jet release to inject drug directly into the small intestine for optimal bioavailability. This transcript may contain forward-looking statements about, among other things, our anticipated operating and financial performance, business plans and prospects; expectations for our product pipeline, in-line products and product candidates, including anticipated regulatory submissions, data read-outs, study starts, approvals, post-approval clinical trial results and other developing data that become available, revenue contribution, growth, performance, timing of exclusivity and potential benefits; manufacturing and product supply; our efforts to respond to COVID-19, including our development of a vaccine to help prevent COVID-19 and our investigational protease inhibitor; our expectations regarding the impact of COVID-19 on our business; plans for and prospects of our acquisitions, dispositions and other business-development activities, and our ability to successfully capitalize on these opportunities; and discussions relating to strategic reviews, capital allocation objectives, dividends and share repurchases, among other things, that involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. 2023 Benzinga.com. CureVac shares were up 4.43% at $40.51 in premarket trading. Pfizer already has multiple compounds aimed at various autoimmune conditions, and this $1.8 billion company seems like an obvious tuck-in acquisition for the pharma giant. Latest patents confirmed it Icing on the cake..Prog is RANKED the #1 Short Squeeze Candidate According to FINTEL & ORTEX . The ideal candidate may already have drugs on the market that could benefit from Pfizer's marketing team. Keep . We have a wide range of tools to help investors make smarter decisions when investing in stocks or options. And, needless to say, the odds of any early stage drug actually making it through Phase 3 . A shelf registration statement relating to the offered shares of common stock was filed with the Securities and Exchange Commission (SEC) on July 30, 2021 and was declared effective on August 6, 2021. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new preclinical or clinical trial data and further analyses of existing preclinical or clinical trial data; risks associated with preliminary data; the risk that clinical trial data are subject to differing interpretations and assessments, including during the peer review/publication process, in the scientific community generally, and by regulatory authorities; whether and when data from the BNT162 mRNA vaccine program will be published in scientific journal publications and, if so, when and with what modifications; whether regulatory authorities will be satisfied with the design of and results from these and future preclinical and clinical studies; whether and when any biologics license applications may be filed in any jurisdictions for any potential vaccine candidates under the collaboration; whether and when any such applications may be approved by regulatory authorities, which will depend on myriad factors, including making a determination as to whether the products benefits outweigh its known risks and determination of the products efficacy and, if approved, whether any such vaccine candidates will be commercially successful; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of any such vaccine candidates, including development of products or therapies by other companies; manufacturing capabilities or capacity, including whether the estimated numbers of doses can be manufactured within the projected time periods indicated; whether and when a future production agreement with the United States will be reached; whether and when other supply agreements will be reached; uncertainties regarding the ability to obtain recommendations from vaccine technical committees and other public health authorities regarding any such vaccine candidates and uncertainties regarding the commercial impact of any such recommendations; and competitive developments.
Mcdonalds Playground For Sale, Articles P